Coherus BioSciences filed a 351(k) biologics license application (BLA) for CHS-1420, an adalimumab biosimilar candidate.
Coherus BioSciences reported that the FDA has accepted for review its biologics license application (BLA) for an adalimumab biosimilar (CHS-1420). The formulation concentration Coherus is seeking was not specified, although the market is swiftly moving away from lower-concentration forms of this agent.
In 2017, the Redwood City, California, company reported topline results from ongoing pharmacokinetic (PK) bioequivalence studies that compared CHS-1420 with a European-marketed version of the reference product (Humira). The company reported that the comparison was based on administration of a 40-mg dose in a group of 216 healthy patients, a trial that met all end points for clinical PK and pharmacodynamic biosimilarity.
By comparison in November, Icelandic company Alvotech indicated that the FDA had accepted its application for a 100-mg/mL dose biosimilar (AVT02). However, Alvotech’s supporting data for the application involved a phase 1 PK similarity study that employed a 40-mg single dose of Humira in healthy subjects and a phase 3 safety and efficacy study that employed an initial loading dose of 80 mg followed by 40 mg every 2 weeks.
In 2016, Coherus reported results from a phase 3 psoriasis study of CHS-1420 that were also positive, demonstrating biosimilarity in patients who achieved a 75% improvement in psoriasis area and severity index measures at week 12. Coherus said CHS-1420 and Humira were “similarly well tolerated with similar safety profiles.” This phase 3 study was intended to support a 351(k) BLA filing in 2017, although that filing was delayed; the company had hoped to achieve a filing by the end of 2020, according to its third-quarter 2020 earnings statement.
Coherus said in its most recent statement that it intends to launch its adalimumab biosimilar in the United States on or after July 1, 2023, under terms agreed upon with AbbVie.
“We are pleased to see the CHS-1420 BLA accepted for review, as we continue to execute on our mission to increase patient access to important medicines and deliver substantial savings to the health care system,” said Denny Lanfear, CEO of Coherus. The company said it anticipates that the US market for adalimumab will be worth $18 billion annually by 2023, representing “substantial pent-up demand” for biosimilar products.
If Coherus brings a low-concentration form of adalimumab to market in 2023, the market may still exist for this version of the blockbuster medication, as competitive pricing may in some cases overcome any disposition on the part of physicians to prefer the higher concentration formulation.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.